Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
if bavi is junk, then how did we get Fast track?
Is this fantasy or fact? You be the judge.
Years ago when PPHM was working with NIAID, FDA, and USAMRIID we never learned the results of this research. The only thing we know now is that these agencies are no longer interested in BAVI. hmmm...
It simple to me why the secrecy. ATMing shares a $1.75 is your answer. Once the cat it out of the bag ATMing will be at much lower levels with OTCBB land the next stop.
Tough Love
If bavi worked as described, you would not be allowed to buy shares for a dollar. Wall Street does not allow blockbuster stocks to trade on the dollar menu.
If liver/breast data was promising PPHM would have unveiled it. The ASCO would have been the appropriate venue. Ask yourself, why the secrecy?
Sorry, I know this hurts but this board needs a little more tough love.
Would someone explain to Jeff where this $79 million came from.
So, how do you know for a fact that Lytle is really using the ATM to pay for salaries?
Cancer Immunotherapy Pipeline
I wonder how not being included in this list will effect patient recruitment? You can't make this stuff up. It's truly remarkable how forgiving most of you are. Investors should be brandishing pitchforks not connecting invisible dots.
http://www.cancerresearch.org/cancer-immunotherapy/cancer-immunotherapy-pipeline
biopharm,
Are you aware of Anti-TIM?
Does the immune system see tumors as foreign or self?
http://dx.doi.org/10.1146/annurev.immunol.21.120601.141135
Natural innate and adaptive immunity to cancer
http://dx.doi.org/10.1146/annurev-immunol-031210-101324
Cancer immunotherapy comes of age
http://dx.doi.org/10.1038/nature10673
Raising the bar: the curative potential of human cancer immunotherapy
http://dx.doi.org/10.1126/scitranslmed.3003634
Polarized immune responses differentially regulate cancer development
http://dx.doi.org/10.1111/j.1600-065X.2008.00600.x
Hallmarks of cancer: the next generation
http://dx.doi.org/10.1016/j.cell.2011.02.013
Immunity, inflammation, and cancer
http://dx.doi.org/10.1016/j.cell.2010.01.025
A cytokine-mediated link between innate immunity, inflammation, and cancer
http://dx.doi.org/10.1172/JCI31537
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion
http://dx.doi.org/10.1126/science.1203486
The three Es of cancer immunoediting
http://dx.doi.org/10.1146/annurev.immunol.22.012703.104803
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
http://dx.doi.org/10.1038/nature01112
Coordinated regulation of myeloid cells by tumours
http://dx.doi.org/10.1038/nri3175
The blockade of immune checkpoints in cancer immunotherapy
http://dx.doi.org/10.1038/nrc3239
Immunosuppressive networks in the tumor environment and their therapeutic relevance
http://dx.doi.org/10.1038/nrc1586
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
http://dx.doi.org/10.1038/nm863
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
http://dx.doi.org/10.1084/jem.20050930
Neutralizing tumor-promoting chronic inflammation: a magic bullet?
http://dx.doi.org/10.1126/science.1232227
Tumor promotion via injury- and death-induced inflammation
http://dx.doi.org/10.1016/j.immuni.2011.09.006
Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion
http://dx.doi.org/10.1084/jem.20090397
TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells
http://dx.doi.org/10.1016/j.stem.2010.11.014
TIM family of genes in immunity and tolerance
http://dx.doi.org/10.1016/S0065-2776(06)91006-2
Tim3 binding to galectin-9 stimulates antimicrobial immunity
http://dx.doi.org/10.1084/jem.20100687
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
http://dx.doi.org/10.1038/ni.2376
Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice
http://dx.doi.org/10.1172/JCI32562
T cell Ig and mucin 1 (TIM-1) is expressed on in vivo-activated T cells and provides a costimulatory signal for T cell activation
http://dx.doi.org/10.1073/pnas.0508643102
TIM-1 induces T cell activation and inhibits the development of peripheral tolerance
http://dx.doi.org/10.1038/ni1186
Anti-T-cell Ig and mucin domain-containing protein 1 antibody decreases TH2 airway inflammation in a mouse model of asthma
http://dx.doi.org/10.1016/j.jaci.2005.08.031
Tim-1 stimulation of dendritic cells regulates the balance between effector and regulatory T cells
http://dx.doi.org/10.1002/eji.201040993
TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells
http://dx.doi.org/10.1016/j.immuni.2007.11.011
TIM family proteins promote the lysosomal degradation of the nuclear receptor NUR77
http://dx.doi.org/10.1126/scisignal.2003200
The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C-monocytes
http://dx.doi.org/10.1038/ni.2063
NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis
http://dx.doi.org/10.1161/CIRCRESAHA.111.253377
Tim-2 regulates T helper type 2 responses and autoimmunity
http://dx.doi.org/10.1084/jem.20050308
Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2
10.1038/nature01037
http://dx.doi.org/10.1038/nature01037
Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis
http://dx.doi.org/10.1038/nature12428
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
http://dx.doi.org/10.1038/nm1093
CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice
http://dx.doi.org/10.1158/0008-5472.CAN-04-3104
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent
http://dx.doi.org/10.1016/j.ccr.2005.04.014
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
http://dx.doi.org/10.1038/415536a
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
http://dx.doi.org/10.1038/ni1271
Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion
http://dx.doi.org/10.1038/nm.2871
Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection
http://dx.doi.org/10.1084/jem.20081398
Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells
http://dx.doi.org/10.1128/JVI.00639-09
Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma
http://dx.doi.org/10.1002/hep.25777
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
http://dx.doi.org/10.1182/blood-2010-10-310425
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
http://dx.doi.org/10.1084/jem.20100637
TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression
http://dx.doi.org/10.1371/journal.pone.0030676
Putting the brakes on anticancer therapies: suppression of innate immune pathways by tumor-associated myeloid cells
http://dx.doi.org/10.1016/j.molmed.2013.06.001
Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity
http://dx.doi.org/10.1182/blood-2011-11-392951
Microenvironmental regulation of metastasis
http://dx.doi.org/10.1038/nrc2618
Identification of Tim4 as a phosphatidylserine receptor
http://dx.doi.org/10.1038/nature06307
Phosphatidylserine receptor Tim-4 is essential for the maintenance of the homeostatic state of resident peritoneal macrophages
http://dx.doi.org/10.1073/pnas.0910929107
T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice
http://dx.doi.org/10.1073/pnas.0910359107
TIM-4, a receptor for phosphatidylserine, controls adaptive immunity by regulating the removal of antigen-specific T cells
http://dx.doi.org/10.4049/jimmunol.1001360
Milk fat globule epidermal growth factor-8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms
http://dx.doi.org/10.1084/jem.20082614
Immunobiology of the TAM receptors
http://dx.doi.org/10.1038/nri2303
Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas
Cancer Immunol Immunother
http://dx.doi.org/10.1007/s00262-012-1371-9
Cell death in the neighborhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues
http://dx.doi.org/10.1002/path.2792
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
http://dx.doi.org/10.1084/jem.20100643
Anti-TIM3 antibody promotes T cell IFN-[ggr]-mediated antitumor immunity and suppresses established tumors Cancer Res
http://dx.doi.org/10.1158/0008-5472.CAN-11-0096
Expression of tumour-specific antigens underlies cancer immunoediting Nature
http://dx.doi.org/10.1038/nature10803
Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression Cancer Cell
http://dx.doi.org/10.1016/j.ccr.2010.11.011
Improved survival with ipilimumab in patients with metastatic melanoma
http://dx.doi.org/10.1056/NEJMoa1003466
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
http://dx.doi.org/10.1056/NEJMoa1200690
Apparently PPHM is not the only company trying to disable these PS immunosuppression signals. That should scare the bejesus out pphm fans.
Peregrine Again Escapes Investor Suit Over Lung Cancer Drug
http://www.law360.com/articles/534773/peregrine-again-escapes-investor-suit-over-lung-cancer-drug
Sorry if already posted.
Wanna read third party validations go look up jazzbeerman posts from years back. 8-9 years ago I was impressed with his research. Looking back monetarily, worst mistake ever. They say history repeats itself but hopefully this time well...
http://investorshub.advfn.com/Peregrine-Pharmaceuticals-PPHM-2076/
Why do you think this is a great find?
Merck was the source so that would explain why PS was not mentioned.
For those of you who think trial begins before 2014 I ask why do you think that?
I'm trying to help so please post your responses and let the interventions begin.
every once in awhile a voice in the back of my head whispers
Exactly, sometimes I get the feeling this thread is moderated by a pump and dump crew.
Peer comparison is one of the most widely used and accepted methods of equity analysis used by professional analysts and by individual investors.
Why in the world is this method censored hear? Please someone explain.
See another one just got deleted. Hopefully some had a chance to read. Apparently comparable analysis examples are prohibited here.
Comparable Company Analysis disprove your Masterpieces take time analogy. Apples to Apples, PPHM is junk. The point is that valuations in biotechnology are supposed to mean something. Valuations are intended to reflect data, peak sales potential, and a company's likelihood of an eventual FDA approval. The higher the valuation, the higher the expectations and vice versa.
Comparing PPHM to PCYC is apples to oranges. Comparing PPHM to CLDX is apples to apples. CLDX has a 2B market cap and pphm roughly 10% of that, WHY? Big red flag IMO.
PPHM will need an approved product with revenue growth to create urgency apparently. If petri dish to PIII approval did not conceive urgency what else will. This is not a shareholder friendly company. The odds of getting bavi this far with no rewards is an abomination.
That's the issue I'm trying to raise without actually saying it and coming at it from a different direction. People need to realize the magnitude of the discount the market has levied against PPHM. When comparing these 2 companies, and yes they are both apples, it's jaw dropping.
Try this on for size geo.
Groupon CEO fired; takes responsibility for company's poor
performance
http://www.zdnet.com/groupon-ceo-fired-takes-responsibility-for-companys-poor-performance-7000011985/
.24 pre split and management is getting rewarded. LOL!
Prepare for worst case scenario/crash landing on the 25th, this is PPHM remember.
What would be a worst case scenario, anyone?
PPHM could absolutely run a PIII trial on their own. And if they do divide your shares by 5.
Full Time Employees
Thu, Dec 30, 2010
Full Time Employees: 139
Thu, Oct 13, 2011
Full Time Employees: 154
Wed, Jan 11, 2012
Full Time Employees: 154
Tue, Apr 23, 2013
Full Time Employees: 172
Sun, May 12, 2013
Full Time Employees: 172
Tue, Oct 29, 2013
Full Time Employees: 182
BINGO!
I think you are seeing it the wrong way. It appears to me someone is supporting the stock. With the idea of going alone floating around we should be under a buck. Going alone in my opinion leads to another reverse split. So at the end of the day hanging around 1.40 is nothing short of a miracle.
This is a point of interest. Is someone/something supporting PPHM? We should be dropping like a rock after Garnick's remarks about BTD.
Is it feasible that "IF" all Big Pharma and the FDA knows that PS is the target and "EVERY" cancer drug will benefit as seen in solid tumors blah blah blah
What's the next mirage?
You are right. I didn't just read this.
Best case scenario we announce what amounts to a functional cure for lung cancer based on pre-clinical results. I'll go with that for now.
Not PPHM because she says theses companies, 4 of them, are working as fast as they can. PPHM not know what fast is unless you are talking ATM usage.
What is that worth????
Not questioning the unforthcoming. I'm questioning the third party responses. People type like PPHM is brewing a panacea, but after further examination, AbbVie/FDA, we get the old adage.. Yeah, I'll pass. PPHM has the Golden Goose but apparently nobody is hunger.
If PPHM goes it alone, I guarantee another REVERSE SPLIT.
How pathetic is the word another in this context?
.40 cents away folks and with the amount of dilution on it's way...
The RS buoy detectors are already signaling.
Hedge his short position?
Did PPHM apply for either AA or BTD? If yes, why was it denied? If no, why not?
What did AbbVie discover that keeps them at bay? PPHM was a go and now that the dust has settled... not so much. hmmm?
If you look for truth, you may find comfort in the end; if you look for comfort you will not get either comfort or truth only soft soap and wishful thinking to begin, and in the end, despair.
C. S. Lewis
All truth passes through three stages. First, it is ridiculed. Second, it is violently opposed. Third, it is accepted as being self-evident.
Arthur Schopenhauer
Smells like a deal...Buyout Oncology? Partner? Merger?
Who's supporting the share price? We should be plummeting. When King speaks we always go down, especially after this train wreck.